High-Risk Large B-Cell Lymphoma

ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma

VJHemOnc – Video Journal of Hematology & HemOnc

ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL) Regimens

Understanding High-Risk DLBCL

Patient Empowerment Network

Insights into the ZUMA-23 trial: axi-cel in frontline high-risk LBCL

VJHemOnc – Video Journal of Hematology & HemOnc

Should we treat high-risk DLBCL differently?

VJHemOnc – Video Journal of Hematology & HemOnc

Venetoclax + Pola-R-CHP for High-Risk B-Cell Lymphoma | Catherine Diefenbach, MD | #ASH24

HealthTree Foundation for Blood Cancers

How to define and treat high-risk lymphoma

VJHemOnc – Video Journal of Hematology & HemOnc

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Lymphoma Research Foundation

High-Risk Lymphoma: The ZUMA-1 and SCHOLAR-1 Trials

Traditional Therapies for High-Risk Lymphoma and Efficacy

Identifying high-risk DLBCL and optimizing treatment for these patients

VJHemOnc – Video Journal of Hematology & HemOnc

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL

VJHemOnc – Video Journal of Hematology & HemOnc

Debate: Should DLBCL Patients be Treated Differently Based on Cell of Origin? - Yes

ZUMA-12: Is CAR T-cell therapy effective in high-risk DLBCL as first-line therapy?

Diffuse Large B Cell Lymphoma - Overview of Standard Therapy with Michael Dickinson

Lymphoma Australia

Azacitidine Plus R-CHOP in High-Risk DLBCL

Targeted Oncology

ICAHO 2016 - Venugopal - High Risk DLBCL

Binaytara Foundation

Introduction of a High-Risk Follicular Lymphoma Patient

Targeted Oncology

Finding the Right Therapy for High-Risk Mantle Cell Lymphoma